TABLE 4.
Comparison of clinicopathologic characteristics between high and low SMI
| Variables | Low SMI (N = 51) | High SMI (N = 81) | p Value |
|---|---|---|---|
| Age (years) | 73 (36–81) | 69 (51–85) | 0.474 |
| BMI (kg/m2) | 23.60 (18.72–29.30) | 24.21 (18.51–30.86) | 0.103 |
| ECOG score | |||
| 0 or 1 | 33 (64.71%) | 53 (65.43%) | 0.932 |
| 2 | 18 (35.29%) | 28 (34.57%) | |
| ISUP grading group | |||
| 1 | 0 (0%) | 12 (14.81%) | <0.001 |
| 2 | 3 (5.88%) | 19 (23.46%) | |
| 3 | 8 (15.69%) | 26 (32.10%) | |
| 4 | 26 (50.98%) | 19 (23.46%) | |
| 5 | 14 (27.45%) | 5 (6.17%) | |
| Clinical T stage | |||
| 2 | 6 (11.76%) | 15 (18.52%) | 0.010 |
| 3 | 15 (29.41%) | 40 (49.38%) | |
| 4 | 30 (58.82%) | 26 (32.10%) | |
| ADT duration before AA | |||
| <12 months | 41 (80.39%) | 26 (32.10%) | <0.001 |
| ≥12 months | 10 (19.61%) | 55 (67.90%) | |
| Metastatic sites | |||
| Bone only | 15 (29.41%) | 49 (60.49%) | 0.001 |
| Viscera | 36 (70.59%) | 32 (39.51%) | |
| PSA at diagnosis (ng/ml) | 13.10 (4.10–96.00) | 13.30 (4.78–57.10) | 0.944 |
| PSA at abiraterone start (ng/ml) | 11.23 (1.11–91.76) | 9.48 (1.12–77.07) | 0.383 |
| PSA nadir after AA treatment (ng/ml) | 3.37 (0.02–39.28) | 7.88 (0.11–48.12) | 0.019 |
| PSA reduction (%) | 29.05 (−64.83–98.34) | 2.61 (−87.10–99.51) | <0.001 |
| Biochemical progression | |||
| Yes | 47 (92.16%) | 51 (62.96%) | <0.001 |
| No | 4 (7.84%) | 30 (37.04%) | |
| Radiological progression | |||
| Yes | 43 (84.31%) | 42 (51.85%) | <0.001 |
| No | 8 (15.69%) | 39 (48.15%) |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group performance status score; ISUP, International Society of Urological Pathology; PSA, prostate‐specific antigen; SMI: skeletal muscle index.